Trial Profile
NEO-SPACE Trial: Neoadjuvant Pembrolizumab-Gemcitabine-Cisplatin Followed by Concurrent Pembrolizumab-Chemoradiation and Maintenance Pembrolizumab for Stage IVA Nasopharyngeal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Cisplatin; Gemcitabine
- Indications Carcinoma; Cholangiocarcinoma; Lung cancer; Nasopharyngeal cancer
- Focus Therapeutic Use
- Acronyms NEO-SPACE Trial
- 05 Feb 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 05 Feb 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 06 Jun 2023 Results (May 2019 to June 2022) assessing the safety and efficacy of pembrolizumab-gemcitabine-cisplatin and CRT in stage IVA nasopharyngeal cancer patients, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.